


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.13%
+0.13%
+0.21%
+2.57%
+1.53%
TEVA
Teva Pharma
$20.48
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Investors confidence is positive
Chart
$19.96 (+2.61%)
$16.37 (+25.11%)
$17.31 (+18.31%)
$16.75 (+22.27%)
TEVA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

TEVA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
TEVA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TEVA Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayTEVA Earnings
The TTM reflects 12-month period, providing review of TEVA financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
SNY
50.58
-0.71%
PFE
24.65
+1.42%
NVS
123.79
+0.96%
MRK
85.98
-0.35%
AZN
82.40
+0.07%
What is TEVA current stock price?
What are TEVA stock strengths?
What risks are associated with TEVA stock?
When is TEVA next earnings report?
What is TEVA market cap and volume?
What is TEVA's current Stock IQ?
Should I buy TEVA stock right now?
Is TEVA a Strong Buy right now?
What does a 'Strong Buy' rating mean for TEVA?
What does a 'Strong Sell' rating mean for TEVA?
What factors influence TEVA's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.13%
+0.13%
+0.21%
+2.57%
+1.53%
TEVA
Teva Pharma
Current Price
$20.48
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Investors confidence is positive
Linked to TEVA
SNY
50.58
-0.71%
PFE
24.65
+1.42%
NVS
123.79
+0.96%
MRK
85.98
-0.35%
AZN
82.40
+0.07%

Chart
$19.96 (+2.61%)
$16.37 (+25.11%)
$17.31 (+18.31%)
$16.75 (+22.27%)
TEVA Analysts Opinion
TEVA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
TEVA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TEVA Street view is extremely bullish and have positive views on the near-term outlook
TEVA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Average key support and resistance price levels.
TEVA Earnings
The TTM data reflects the most recent 12-month period, providing overview of TEVA financial performance.
TEVA Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
TEVA Latest Analysis
Teva Recalls Over 580000 Bottles Of Blood Pressure Drug Over Cancer Risk Concern . (RTTNews) - Over half a million bottles of the blood pressure drug prazosin hydrochloride have been recalled by the United States Food and Drug Administration because of potential contamination with a chemical that causes cancer.
Fri Oct 31, 2025
Notable ETF Inflow Detected - DBEF SE CYBR TEVA. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the X-trackers MSCI EAFE Hedged Equity Fund (Symbol: DBEF) where we have detected an approximate $201.9 million dollar inflow -- thats a 2.5% increase w
Fri Oct 31, 2025
IDEV AER TEVA GRAB: ETF Inflow Alert. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core MSCI International Developed Markets ETF (Symbol: IDEV) where we have detected an approximate $254.2 million dollar inflow -- thats a 1
Thu Oct 23, 2025
All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy. Teva Pharmaceutical Industries (TEVA) has been upgraded to a Zacks Rank #2 (Buy) reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Tue Oct 21, 2025
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?. The consensus price target hints at a 28.1% upside potential for Teva Pharmaceutical Industries (TEVA). While empirical research shows that this sought-after metric is hardly effective an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tue Oct 21, 2025
Formycon Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe . (RTTNews) - Formycon AG (FYB.F) Bioeq AG and Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday announced the launch of FYB201/Ranivisio or ranibizumab in Europe as the first Lucentis biosimilar available in pre-filled syringe presentation or PFS approved by European Medicine
Tue Oct 21, 2025
Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA) Keeps a Buy. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 9 Jason Gerberry from Bank of America Securities raised the firms price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) from $22 to $24 while keeping a Buy rating on the stock. The analyst noted that [….]
Tue Oct 21, 2025
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe. TEL AVIV Israel Oct. 20 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) entered into a license agreement with Prestige Biopharma for the commercialization of Tuznue® (trastuzumab) a biosimilar to Herceptin® across a majority of European markets.
Mon Oct 20, 2025
Teva Pharmaceutical Receives FDA Approval to Expand UZEDY Indication for Maintenance Treatment of Bipolar I Disorder.
Fri Oct 17, 2025
Heres Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Thu Oct 16, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
TEVA Stock trends
TEVA Stock performance
TEVA Stock analysis
TEVA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.